肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后

2018-06-14 MedSci MedSci原创

嵌合抗原CD19非霍奇金淋巴瘤T细胞
关注

经嵌合抗原受体（CAR）T细胞治疗后，白介素（IL）-15升高和CAR T细胞扩增与非霍奇金淋巴瘤（NHL）的预后相关。但是，预注射CAR产品的T细胞功能与临床预后的关联尚未有报道。近日，Blood杂志上发表一篇相关文献，研究人员对预注射CD19NHL患者的CAR产品进行单细胞分析发现CAR产品包括多功能的T细胞亚集，可涉及以细胞因子和趋化因子（包括IFN-γ、IL-17A和巨噬细胞炎性蛋白1-α

经嵌合抗原受体（CAR）T细胞治疗后，白介素（IL）-15升高和CAR T细胞扩增与非霍奇金淋巴瘤（NHL）的预后相关。但是，预注射CAR产品的T细胞功能与临床预后的关联尚未有报道。近日，Blood杂志上发表一篇相关文献，研究人员对预注射CD19NHL患者的CAR产品进行单细胞分析发现CAR产品包括多功能的T细胞亚集，可涉及以细胞因子和趋化因子（包括IFN-γ、IL-17A和巨噬细胞炎性蛋白1-α）为代表的多重免疫程序。

预先设定的T细胞多功能强度指数（PSI）应用于预注射的CAR产品与临床反应性显著相关；PSI与CAR T细胞扩增或预处理血清IL-15水平相结合，可产生额外的效益。在产品细胞总数中，多功能的CD4+T细胞与临床预后的相关性强于CD8+细胞的。

3级以上的细胞因子释放综合征与多功能T细胞相关，3级以上的神经毒性（NT）和抗肿瘤效应均与多功能的产生IL-17A的T细胞相关。

本研究结果显示预注射CAR产品中具有特定多功能的T细胞亚集可改善CAR T细胞疗法的临床预后。

原始出处：

John Rossi， et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL. Blood  2018  ：blood-2018-01-828343；  doi： https：//doi.org/10.1182/blood-2018-01-828343

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 dingxiaobo

    #CD19#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 yzh402

    #NHL#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 budeshao

    #临床预后#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 xiaoyeshuang

    #抗原#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 dangious

    #嵌合抗原受体#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534724, encodeId=16f51534e24a3, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623294, encodeId=baf516232943e, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626737, encodeId=5e0c1626e37d1, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Sat Jun 16 05:01:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324307, encodeId=519b32430eac, content=在学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1784b52cf63d32ab4b8fb581563ad197/35d724e6c56f9ba392ff215b22fe0948.jpg, createdBy=8c702381169, createdName=满怀抱负的小医生, createdTime=Fri Jun 15 06:50:45 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-15 满怀抱负的小医生

    在学习

    0